Savior Lifetec - Asset Resilience Ratio
Savior Lifetec (4167) has an Asset Resilience Ratio of 18.86% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 4167 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Savior Lifetec's Asset Resilience Ratio has changed over time. See 4167 net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Savior Lifetec's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Savior Lifetec market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$789.00 Million | 18.86% |
| Total Liquid Assets | NT$789.00 Million | 18.86% |
Asset Resilience Insights
- Good Liquidity Position: Savior Lifetec maintains a healthy 18.86% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Savior Lifetec Industry Peers by Asset Resilience Ratio
Compare Savior Lifetec's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Savior Lifetec (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Savior Lifetec.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 18.86% | NT$789.00 Million ≈ $24.86 Million |
NT$4.18 Billion ≈ $131.82 Million |
+1.47pp |
| 2024-12-31 | 17.39% | NT$761.06 Million ≈ $23.98 Million |
NT$4.38 Billion ≈ $137.87 Million |
+10.74pp |
| 2023-12-31 | 6.65% | NT$254.27 Million ≈ $8.01 Million |
NT$3.82 Billion ≈ $120.44 Million |
-6.14pp |
| 2022-12-31 | 12.79% | NT$563.76 Million ≈ $17.76 Million |
NT$4.41 Billion ≈ $138.90 Million |
+12.44pp |
| 2021-12-31 | 0.35% | NT$15.71 Million ≈ $495.01K |
NT$4.54 Billion ≈ $142.99 Million |
-2.13pp |
| 2020-12-31 | 2.47% | NT$119.65 Million ≈ $3.77 Million |
NT$4.84 Billion ≈ $152.38 Million |
+1.88pp |
| 2019-12-31 | 0.60% | NT$24.13 Million ≈ $760.13K |
NT$4.03 Billion ≈ $127.07 Million |
-1.60pp |
| 2018-12-31 | 2.19% | NT$77.42 Million ≈ $2.44 Million |
NT$3.53 Billion ≈ $111.20 Million |
+2.18pp |
| 2017-12-31 | 0.01% | NT$420.00K ≈ $13.23K |
NT$3.95 Billion ≈ $124.37 Million |
-- |
About Savior Lifetec
Savior Lifetec Corporation, a specialty injectable company, develops, produces, and supplies sterile active pharmaceutical ingredients and finished dosage formulations. The company provides various carbapenem generic drugs and injections, such as paliperidone palmitate, cetrorelix and ganirelix acetate, plecanatide, prucalopride succinate, and brinzolamide. It offers imipenem and cilastatin, mero… Read more